A number of peptide vaccines against ovarian cancer are currently in clinical trials (Table 4), such as NY-ESO-1 peptide vaccine (116), folic acid receptor α peptide vaccine (120), HER-2/neu peptide vaccine (117), P53 synthetic long peptide vaccine (p53-SLP) (118), and WT1 peptide vaccine (119). This evidence concerns the gene ERBB2 and ovarian carcinoma.